Alena Ivanova
Overview
Explore the profile of Alena Ivanova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
5504
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ivanova A, Chalupska R, Louro A, Firth M, Gonzalez-King Garibotti H, Hultin L, et al.
Adv Sci (Weinh)
. 2025 Jan;
12(10):e2407850.
PMID: 39823165
Targeted delivery of therapeutic agents is a persistent challenge in modern medicine. Recent efforts in this area have highlighted the utility of extracellular vesicles (EVs) as drug carriers, given that...
2.
Ivanova A, Kohl F, Gonzalez-King Garibotti H, Chalupska R, Cvjetkovic A, Firth M, et al.
Sci Rep
. 2024 May;
14(1):12177.
PMID: 38806609
Heart failure remains a leading cause of mortality. Therapeutic intervention for heart failure would benefit from targeted delivery to the damaged heart tissue. Here, we applied in vivo peptide phage...
3.
Gonzalez-King H, Rodrigues P, Albery T, Tangruksa B, Gurrapu R, Silva A, et al.
J Extracell Vesicles
. 2024 May;
13(5):e12445.
PMID: 38711334
Small extracellular vesicles (sEV) derived from various cell sources have been demonstrated to enhance cardiac function in preclinical models of myocardial infarction (MI). The aim of this study was to...
4.
Ivanova A, Badertscher L, ODriscoll G, Bergman J, Gordon E, Gunnarsson A, et al.
Adv Sci (Weinh)
. 2023 Oct;
10(34):e2304389.
PMID: 37867228
Efficient and targeted delivery of therapeutic agents remains a bottleneck in modern medicine. Here, biochemical engineering approaches to advance the repurposing of extracellular vesicles (EVs) as drug delivery vehicles are...
5.
Lions C, Laroche H, Zaegel-Faucher O, Ressiot E, Bregigeon S, Geneau de Lamarliere P, et al.
Eur J Gastroenterol Hepatol
. 2019 Dec;
32(9):1212-1221.
PMID: 31851097
Objective: Treatment recommendations for hepatitis C now make no distinction between HIV/HCV-coinfected and HCV-monoinfected patients. The largest challenge remained lack of effective models to eliminate HCV in people living with...
6.
Thery C, Witwer K, Aikawa E, Alcaraz M, Anderson J, Andriantsitohaina R, et al.
J Extracell Vesicles
. 2019 Jan;
7(1):1535750.
PMID: 30637094
The last decade has seen a sharp increase in the number of scientific publications describing physiological and pathological functions of extracellular vesicles (EVs), a collective term covering various subtypes of...
7.
Aliper A, Belikov A, Garazha A, Jellen L, Artemov A, Suntsova M, et al.
Aging (Albany NY)
. 2016 Sep;
8(9):2127-2152.
PMID: 27677171
Populations in developed nations throughout the world are rapidly aging, and the search for geroprotectors, or anti-aging interventions, has never been more important. Yet while hundreds of geroprotectors have extended...
8.
Suntsova M, Garazha A, Ivanova A, Kaminsky D, Zhavoronkov A, Buzdin A
Cell Mol Life Sci
. 2015 Jun;
72(19):3653-75.
PMID: 26082181
Human endogenous retroviruses (HERVs) and related genetic elements form 504 distinct families and occupy ~8% of human genome. Recent success of high-throughput experimental technologies facilitated understanding functional impact of HERVs...
9.
Garazha A, Ivanova A, Suntsova M, Malakhova G, Roumiantsev S, Zhavoronkov A, et al.
Cell Cycle
. 2015 Apr;
14(9):1476-84.
PMID: 25853282
Endogenous retroviruses (ERVs) and LTR retrotransposons (LRs) occupy ∼8% of human genome. Deep sequencing technologies provide clues to understanding of functional relevance of individual ERVs/LRs by enabling direct identification of...